VRDN
Viridian Therapeutics, Inc. (VRDN) ESG Analysis Analysis (2026)
Overall Score
Environmental
No material environmental disclosure or sustainability metrics were provided this month.
The company remains pre-profit and R&D-heavy, so near-term environmental footprint is not clearly evidenced by the available financial data.
Social
No material social disclosure or workforce metrics were provided this month.
High R&D intensity and negative operating margins suggest continued dependence on specialized talent, but there is no new evidence of a change in labor or customer-related risk.
Governance
No material governance disclosure or board/ownership updates were provided this month.
The balance sheet remains very liquid with a current ratio of 16.9x, but the company is still loss-making and highly valued on sales, which keeps governance and capital-allocation scrutiny elevated.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Viridian Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

